¥2,784.50
2.28%
Tokyo, Sep 18, 03:30 pm JST.
ISIN
JP3982400008
Symbol
4527

Rohto Pharmaceutical Co Target price 2026 - Analyst rating & recommendation

Rohto Pharmaceutical Co Classifications & Recommendation

Buy
73%
Hold
27%

Rohto Pharmaceutical Co Price Target

Target Price ¥3,085.50
Price ¥2,784.50
Potential
Number of Estimates 12
12 Analysts have issued a price target Rohto Pharmaceutical Co 2027 . The average Rohto Pharmaceutical Co target price is ¥3,085.50. This is higher than the current stock price. The highest price target is
¥3,885.00 39.52%
register free of charge
, the lowest is
¥2,626.00 5.69%
register free of charge
.
A rating was issued by 15 analysts: 11 Analysts recommend Rohto Pharmaceutical Co to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Rohto Pharmaceutical Co stock has an average upside potential 2027 of . Most analysts recommend the Rohto Pharmaceutical Co stock at Purchase.

Sales and Margin forecast 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Revenue Billion ¥ 343.73 373.98
11.37% 8.80%
EBITDA Margin 14.80% 16.80%
2.62% 13.54%
Net Margin 9.96% 9.50%
0.83% 4.65%

12 Analysts have issued a sales forecast Rohto Pharmaceutical Co 2027 . The average Rohto Pharmaceutical Co sales estimate is

¥374b
unlock
. This is
5.83% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
¥399b 12.97%
unlock
, the lowest is
¥345b 2.25%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 ¥344b 11.37%
2027
¥374b 8.80%
unlock
2028
¥391b 4.51%
unlock
2029
¥411b 5.15%
unlock

12 Rohto Pharmaceutical Co Analysts have issued a net profit forecast 2027. The average Rohto Pharmaceutical Co net profit estimate is

¥35.5b
unlock
. This is
7.27% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
¥41.5b 25.20%
unlock
, the lowest is
¥32.0b 3.39%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 ¥34.2b 10.45%
2027
¥35.5b 3.76%
unlock
2028
¥37.4b 5.34%
unlock
2029
¥39.2b 4.61%
unlock

Net Margin

2026 9.96% 0.83%
2027
9.50% 4.65%
unlock
2028
9.58% 0.84%
unlock
2029
9.53% 0.52%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Earnings Per Share ¥ 145.28 157.27
7.27% 8.25%
P/E 17.71
EV/Sales 1.70

12 Analysts have issued a Rohto Pharmaceutical Co forecast for earnings per share. The average Rohto Pharmaceutical Co EPS is

¥157.27
unlock
. This is
8.73% higher
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
¥183.55 26.90%
unlock
, the lowest is
¥141.64 2.07%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 ¥145.28 7.27%
2027
¥157.27 8.25%
unlock
2028
¥165.66 5.33%
unlock
2029
¥173.30 4.61%
unlock

P/E ratio

Current 19.25 12.30%
2027
17.71 8.01%
unlock
2028
16.81 5.08%
unlock
2029
16.07 4.40%
unlock

Based on analysts' sales estimates for 2027, the Rohto Pharmaceutical Co stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.80
2027
1.70 5.69%
unlock
2028
1.62 4.31%
unlock
2029
1.54 4.90%
unlock

P/S ratio

Current
2027
1.77 5.51%
unlock
2028
1.69 4.31%
unlock
2029
1.61 4.90%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today